Health
Sanofi and GSK start Phase II study of their COVID-19 vaccine candidate – European Pharmaceutical Review
The dose finding study will assess the safety, reactogenicity and immunogenicity of the investigational COVID-19 vaccine in 720 participants.
Posted: 24 February 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies investigational COVID-19 vaccine in 720 participants.
Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study of their adjuvanted recombinant protein COVID-19 vaccine candidate.
The Phase II trial is a randomised, double-blind, multi-centre dose finding study and will evaluate…
-
Noosa News22 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News23 hours agoMotorcyclist dies in crash with truck
-
Noosa News23 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
Noosa News21 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush